Shionogi & Co., Ltd announces that Naldemedine meets the primary endpoint in a Phase 3 study for the treatment of opiod-induced constipation
30 Mar 2015
30.03.2015 Shionogi & Co., Ltd announces that Nademedine meets the primary endpoint in a Phase 3 study for the treatment of opiod-induced constipation
Shionogi Limited. Registered in England and Wales No. 07945432. Registered office: 33 Kingsway. London WC2B 6UF, UK.
Report Side Effect
Just to let you know, you are now moving to another website this is not under our control and Shionogi Limited is not responsible for its contents.